Get the Stockscreener App
6.8858
3.42%
-0.2442
After Hours:
1.90
-4.9858
-72.41%
Exicure Inc stock is traded at $6.8858, with a volume of 281.22K.
It is down -3.42% in the last 24 hours and up +12.88% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$7.13
Open:
$7.0883
24h Volume:
281.22K
Relative Volume:
2.91
Market Cap:
$43.50M
Revenue:
$28.83M
Net Income/Loss:
$-13.34M
P/E Ratio:
-4.5301
EPS:
-1.52
Net Cash Flow:
$-7.49M
1W Performance:
-12.31%
1M Performance:
+12.88%
6M Performance:
-38.68%
1Y Performance:
+178.27%
1-Day Range:
$6.7142
$7.37
1-Week Range:
$6.52
$8.25
52-Week Range:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.65 | 833.82M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.31 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.82 | 120.57M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.152 | 320.01M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.63 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
When is Exicure Inc. stock expected to show significant growthUnlock exclusive stock market forecasts - jammulinksnews.com
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Lelezard
What risks could impact Exicure Inc. stock performanceConsistent Gain Plan with AI Support - Newser
Multi asset correlation models including Exicure Inc.Pattern Recognition Tool for ROI Investors - Newser
Using data models to predict Exicure Inc. stock movementFree Entry Zone Strategy for Consistent Profit - Newser
Exicure's GPC-100: A Game-Changer in Stem Cell Mobilization with Near-Term Data Catalysts - AInvest
Custom strategy builders for tracking Exicure Inc.AI Triggered Buy Zone Forecast System - Newser
Exicure's GPC-100: A High-Stakes Gamble in Myeloma Stem Cell Mobilization - AInvest
Analyzing Exicure Inc. with multi timeframe chartsTechnical Setup and Return Forecast Engine - Newser
How does Exicure Inc. compare to its industry peersEntry Signal Signals To Watch Now - jammulinksnews.com
What institutional investors are buying Exicure Inc. stockChart Pattern Updates With High Returns - jammulinksnews.com
Stocks to Watch: Exicure, TTEC - MarketWatch
Exicure completes last patient in Phase 2 GPC-100 combo trial - TipRanks
Exicure stock surges after completing Phase 2 trial enrollment By Investing.com - Investing.com Nigeria
Exicure stock surges after completing Phase 2 trial enrollment - Investing.com Australia
Revolutionary 45-Minute Stem Cell Treatment Completes Phase 2 Trial, Replacing Overnight Protocol - Stock Titan
Historical volatility pattern of Exicure Inc. visualizedEntry and Exit Strategy for Swing Traders - Newser
What catalysts could drive Exicure Inc. stock higher in 2025Stock Strategy Ideas For Smart Trading - jammulinksnews.com
Why Exicure Inc. stock attracts strong analyst attentionFree Low Risk Buy Zone Opportunity Watch - Newser
What institutional flow reveals about Exicure Inc.Early Entry Planner for Swing Candidates - Newser
Quant Models Detect Momentum Reversal in Exicure Inc.Trade Setups With AI Powered Filters Published - metal.it
Exicure Inc. Approaches Support With Recovery in SightCommunity Shared Smart Money Signals Show Movement - beatles.ru
What makes Exicure Inc. stock price move sharplyFree AI Trading Suggestions With Accuracy Focus - Newser
How does Exicure Inc. generate profit in a changing economyInvest confidently with data-driven strategies - jammulinksnews.com
What is Exicure Inc. company’s growth strategyUnlock powerful portfolio management tools - jammulinksnews.com
What are the technical indicators suggesting about Exicure Inc.Strong return on assets - jammulinksnews.com
What are Exicure Inc. company’s key revenue driversFind market-beating stocks for your portfolio - jammulinksnews.com
Why is Exicure Inc. stock attracting strong analyst attentionBreakthrough capital growth - jammulinksnews.com
How Efficient Is Exicure Inc. at Controlling Operating CostsProfit Focused Trade Alerts - metal.it
Is it the right time to buy Exicure Inc. stockMaximize your investment portfolio’s performance - jammulinksnews.com
Exicure Inc. Earnings Report Breakdown: What Investors Should KnowLow Risk Profit Ideas - Newser
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):